ClinicalTrials.gg
CompletedNCT02086968Updated Sep 17, 2020Results posted

Treatment Response of Injectafer vs Oral Iron to Baseline Hepcidin Levels in Patients With Iron Deficiency Anemia (IDA) Secondary to Inflammatory Bowel Disease (IBD) or Gastric Bypass

A Phase 4 interventional study of Injectafer and Ferrous Sulfate tablets in Iron Deficiency Anemia Secondary to IBD or Gastric Bypass, sponsored by American Regent, Inc.. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-09-17.

Sponsored by American Regent, Inc. (part of Daiichi Sankyo) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
198
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 57 studies testing ferric carboxymaltose in Anemia, Iron-Deficiency — 7 open to participants now, 7 under way, none of them phase 3. ferric carboxymaltose · Anemia, Iron-Deficiency.

Enrollment
19th of 57
198 · median 100
Started
2014
with 1 other
Phase 4
24 of 57
6 open now
Registered
17th of 57
by date
Lead sponsor
11 of 57
American Regent, Inc.

Among the 57 studies testing ferric carboxymaltose in Anemia, Iron-Deficiency, this one is the 19th largest by enrollment, is one of 2 that started in 2014, is one of 24 in phase 4, and was the 17th registered.

Anemia, Iron-Deficiency

601 studies on the registry are indexed under Anemia, Iron-Deficiency; 96 are open to participants now.

Browse Anemia, Iron-Deficiency studies →

Open to participants now

7 of the 57 studies testing ferric carboxymaltose in Anemia, Iron-Deficiency are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About ferric carboxymaltose

ferric carboxymaltose: first FDA approval 2013 (INJECTAFER). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Anemia, Iron-Deficiency studies recruiting now, 19 (35%) set no upper age limit and 32 (58%) stop at 75 or younger; 16 take children under 18; 17 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies testing ferric carboxymaltose in Anemia, Iron-Deficiency, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the treatment response of Injectafer vs. oral iron to baseline hepcidin levels to determine if any of these select IBD or Gastric Bypass patients may demonstrate to be inappropriate for oral iron therapy.

Read the detailed description

The primary objective of this study is to evaluate the treatment response of Injectafer vs. oral iron in patients with varying hepcidin levels correlating the treatment response/hepcidin levels to more common laboratory parameters such as ferritin and CRP (C-Reactive Protein) levels and possibly determine if any of these select IBD or Gastric Bypass patients may demonstrate to be inappropriate for oral iron therapy.

03

Conditions studied

  • Iron Deficiency Anemia Secondary to IBD or Gastric Bypass
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed
  • Male or female subjects ≥ 18 years of age with clinical diagnosis of IDA secondary to IBD or Gastric Bypass
  • Screening (Hb) ≤ 11g/dL
  • Screening Ferritin ≤ 100 ng/mL
  • Female subjects who are of childbearing age must have a negative pregnancy test at screening and be practicing an acceptable method of during the study

Exclusion criteria

Exclusion Criteria:

  • reaction to any component of IV Injectafer or oral iron
  • Requires dialysis for treatment of chronic kidney disease (CKD)
  • During the 30 day period prior to screening has been treated with IV iron
  • No evidence of iron deficiency
  • During the 30 day period prior to screening has been treated with a red blood cell transfusion.
  • Any non-viral infection
  • Known positive hepatitis with evidence of active disease
  • Received an drug within 30 days of screening
  • Active within 5 years. Basal or squamous cell skin cancer is not exclusionary
  • Alcohol or drug abuse within the past 6 months
  • Hemochromatosis or other iron storage disorders
  • Pregnant
  • Any other laboratory abnormality, medical condition, or psychiatric disorders which in the opinion of the Investigator would put the subject's disease management at risk or may result in the subject being unable to comply with the study requirements
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
198 participants (actual)

Study arms

  • Active comparator
    Injectafer

    2 doses of Injectafer, at 15 mg/kg for a maximum single dose of 750 mg given on Days 0 and 7 for a total of up to 1500 mg

    Drug: Injectafer

  • Active comparator
    Ferrous Sulfate tablets

    Oral Ferrous Sulfate at 325 mg (1 tablet) three times a day for 28 days

    Drug: Ferrous Sulfate tablets

Interventions

  • 2 doses of Injectafer, at 15mg/kg for a maximum single dose of 750mg given on days 0 and 7 for a total of up to 1500mg

    Also known as: Ferric Carboxymaltose (FCM)

  • 325mg (1 tablet) three times a day for 28 days

    Also known as: Oral Iron tablets

06

What researchers measure

Primary outcomes

  1. Correlation Between Screening Hepcidin and Change in Hemoglobin From Baseline to Highest Observed Hemoglobin Change (Proportion of Responders).

    Responders were defined as subjects achieving an increase from baseline ≥2 g/dL at anytime between baseline and the end of the study (Day 28). The relation between screening hepcidin and change in hemoglobin was assessed with regression models with baseline hepcidin and treatment group as independent factors. Treatment group differences (oral vs. IV iron) for mean changes in endpoints were assessed with the analysis of covariance with a fixed factor for treatment and baseline value as covariate. Treatment group differences for proportions were assessed with the normal approximation to the binomial distribution.

    Time frame: anytime between baseline and end of study (day 28) or time of intervention

07

Results

Posted Sep 17, 2020
Limitations and caveats
The study was stopped early due to slow enrollment, however it was not considered prematurely terminated. A total of 198 of the 400 subjects planned were randomized, 196 were treated, and the study concluded normally.

Participant flow

This study was conducted at 41 study centers in the United States. The first subject was screened on 06 February 2014 and the last subject was completed on 07 July 2016.

Participant flow — Overall Study
MilestoneInjectaferFerrous Sulfate Tablets
Started10098
Completed9285
Not completed813
Withdrew: Adverse event15
Withdrew: Lost to follow-up23
Withdrew: Study drug received outside protocol01
Withdrew: Physician decision40
Withdrew: Withdrawal by subject14

Outcome measures

PrimaryCorrelation Between Screening Hepcidin and Change in Hemoglobin From Baseline to Highest Observed Hemoglobin Change (Proportion of Responders).

Responders were defined as subjects achieving an increase from baseline ≥2 g/dL at anytime between baseline and the end of the study (Day 28). The relation between screening hepcidin and change in hemoglobin was assessed with regression models with baseline hepcidin and treatment group as independent factors. Treatment group differences (oral vs. IV iron) for mean changes in endpoints were assessed with the analysis of covariance with a fixed factor for treatment and baseline value as covariate. Treatment group differences for proportions were assessed with the normal approximation to the binomial distribution.

Time frame:
anytime between baseline and end of study (day 28) or time of intervention
Reported as:
Count of participants · Participants
Correlation Between Screening Hepcidin and Change in Hemoglobin From Baseline to Highest Observed Hemoglobin Change (Proportion of Responders).
ParticipantsInjectaferFerrous Sulfate Tablets
Correlation Between Screening Hepcidin and Change in Hemoglobin From Baseline to Highest Observed Hemoglobin Change (Proportion of Responders).6034

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Injectafer0/99 (0%)3/99 (3%)33/99 (33.3%)
Ferrous Sulfate Tablets0/97 (0%)1/97 (1%)24/97 (24.7%)
Most frequent serious events
Most frequent serious events
EventInjectaferFerrous Sulfate Tablets
Crohn's diseaseGastrointestinal disorders0/991/97
Small intestinal obstructionGastrointestinal disorders0/991/97
Colitis ulcerativeGastrointestinal disorders1/990/97
Large intestinal obstructionGastrointestinal disorders1/990/97
Clostridium difficile colitisInfections and infestations1/990/97
Most frequent other events
Showing 10 of 17
Most frequent other events
EventInjectaferFerrous Sulfate Tablets
ConstipationGastrointestinal disorders1/9910/97
Blood phosphorous decreasedInvestigations10/990/97
NauseaGastrointestinal disorders2/996/97
Abdominal painGastrointestinal disorders1/995/97
VomitingGastrointestinal disorders0/995/97
HypophosphataemiaMetabolism and nutrition disorders5/990/97
HeadacheNervous system disorders4/990/97
Abdominal pain upperGastrointestinal disorders0/993/97
DiarrhoeaGastrointestinal disorders0/993/97
Faeces discouleredGastrointestinal disorders0/993/97

Baseline characteristics

Of the 198 subjects randomized, two subjects (one in each group) were not treated.

Age, Continuous
Age, Continuous(years)InjectaferFerrous Sulfate TabletsTotal
Median38.3 (18.6 to 85.5)43.0 (18.5 to 74.3)40.5 (18.5 to 85.5)
Sex: Female, Male
Sex: Female, Male(Participants)InjectaferFerrous Sulfate TabletsTotal
Female7666142
Male233154
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)InjectaferFerrous Sulfate TabletsTotal
White7279151
Black/African American251742
Asian112
American Indian/Alaska Native011
Region of Enrollment
Region of Enrollment(Participants)InjectaferFerrous Sulfate TabletsTotal
United States9997196
Point of Care Hemoglobin
Point of Care Hemoglobin(g/dL)InjectaferFerrous Sulfate TabletsTotal
Mean9.3 ± 1.199.4 ± 0.999.3 ± 1.10
08

Study locations

No study locations are listed for this record.

09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2014 to primary completion in Jul 2016, 30 months.

Results were first posted in Sep 2020, 4 years 2 months after primary completion.

Of 51 phase 4 interventional studies under Anemia, Iron-Deficiency, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 35. This study's 30 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2014
First posted
Mar 13, 2014
StartActual
Jan 1, 2014
Primary completionActual
Jul 16, 2016
CompletionActual
Oct 2017
Results first posted
Sep 17, 2020
Last update
Sep 17, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02086968
Responsible party
Sponsor
First posted
Mar 13, 2014
Start date
Jan 1, 2014
Primary completion
Jul 16, 2016
Completion
Oct 2017
Results posted
Sep 17, 2020
Last update
Sep 17, 2020

Study contacts

Mark A Falone, MD
study director · American Regent, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ferric carboxymaltose · Ferrous sulfate

Start the discussion